Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-01-29
1999-01-12
Cunningham, Thomas M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 551, A61K 37715, A61K 3909
Patent
active
058589910
ABSTRACT:
The method of the present invention provides a means of treating a patient having a wound, especially by minimizing scarring and accelerating wound healing, by administering CM101 or GBS toxin isolated from Group B .beta.-hemolytic streptococcus bacteria. The method of the present invention also includes administration of CM101 or GBS toxin to surgery patients having tumors in order to facilitate wound healing and minimize the likelihood of tumor progression.
REFERENCES:
patent: 4242326 (1980-12-01), Sugawara et al.
patent: 4725609 (1988-02-01), Kull, Jr. et al.
patent: 4882317 (1989-11-01), Marburg et al.
patent: 4895838 (1990-01-01), McCluer et al.
patent: 4912093 (1990-03-01), Michaeli
patent: 5010062 (1991-04-01), Hellerqvist et al.
patent: 5145676 (1992-09-01), Fahey et al.
patent: 5160483 (1992-11-01), Postlethewaite et al.
patent: 5225331 (1993-07-01), Jennings et al.
patent: 5302386 (1994-04-01), Kasper et al.
patent: 5382514 (1995-01-01), Passaniti et al.
Abramovitch, R., et al., Neovascularization Induced Growth of Implanted C6 Glioma Multicellular Spheriods: Magnetic Resonance Microimaging, Cancer Research, 55:1956-1962, (1995).
Arbiser, J.L., MD, Ph.D., et al., Angiogenesis and the Skin: A Primer, J. of the American Academy of Dermatology, 34(3):486-497, (1996).
Augustin, H.G., et al., Ovarian Angiogenesis: Phenotypic characterization of Endothelial Cells in a Physiological Model of Blood Vessel Growth and Regression, Am. J. Pathol., 147(2):339-351, (1995).
Battegay, E.J., Angiogenesis: Mechanistic Insights, Neovascular Diseases, and Therapeutic Prospects, J. Mol. Med., 73:333-346, (1995).
Broadley, K.N., et al., Monospecific Antibodies Implicate Basic Fibroblast Growth Factor in Normal Wound Repair, Lab. Investigation, 61(5):571-575, (1989).
Brown, L.F., et al., Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) by Epidermal Keratinocytes During Wound Healing, J. Exp. Med., 176:1375-1379, (1992).
Brown, L.F., et al., Increased Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Bullous Pemphigoid, Dermatitis Herpetiformis, and Erythema Multiforme, J. Invest. Dermatol., 104(5):744-749, (1995).
Brown, L.F., et al., Overexpression of Vascular Permeability Factor (VPF/VEGF) and its Endothelial Cell Receptors in Delayed Hypersensitivity Skin Reactions, J. Immunol., 154(6):2801-2807, (1995).
Dvorak, H.F., et al., Vascular Permeability Factor/Vascular Endothelial Growth Factor: An Important Mediator of Angiogenesis in Malignancy and Inflammation, Int. Arch. Allergy Immunol., 107:233-235, (1995).
Dvorak, H.F., et al., Vascular Permeability Factor/Vascular Endothelial Growth Factor, Microvascular Hyperpermeability, and Angiogenesis, Am. J. Pathol., 146(5):1029-1039, (1995).
Ferrara, N., The Role of Vascular Endothelial Growth Factor in Pathological Angiogenesis, Breast Cancer Res. Treat., 36:127-137, (1995).
Ferrara, N., et al., Vascular Endothelial Growth Factor, a Specific Regulator of Angiogenesis, Curr. Opin. Nephrol. Hypertens., 5(1):35-44, (1996).
Folkman, J., Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease, Nature Medicine, 1(1):27-31, (1995).
Folkman, J., et al., Angiogenic Factors, Science, 2:442-448, (1987).
Folkman, J., et al., Diagnostic and Therapeutic Applications of Angiogenesis Research, C. R. Acad. Sci. Paris, Sciences de la vie, 316:914-918, (1993).
Gatenby, R.A., et al., Suppression of Wound Healing in Tumor Bearing Animals as a Model for Tumor-Host Interaction: Mechanism of Suppression, Cancer Research, 50:7997-8001, (1990).
Hellerqvist, C.G., et al., CM101 Induces a Compliment-Activated Inflammatory Response Targeting Tumor Neovasculature, Proceedings of the American Assoc. for Cancer Research, Abstract #3328, (1996).
Hellerqvist, C.G., et al., Cytokine Production in Cancer Patients Receiving the Anti-Neovascularization Drug CM-101, Proceedings of ASCO, Abstract #1592, vol. 14, (1995).
Hellerqvist, C.G., et al., Studies on Group B .beta.-Hemolytic Streptococcus I. Isolation and Partial Characerization of an Extra-Cellular Toxin, Pediatr. Res., 15:892-898, (1981).
Hellerqvist, C.G., et al., Antitumor Effects of GBS Toxin: a Polysaccharide Exotoxin From Group B .beta.-Hemolytic Streptococcus, J. Canc. Res. Clin. Oncol., 120:63-70, (1993).
Hellerqvist, C.G., et al., Early Results of a Phase I Trial of CM101 in Cancer Patients, Proceedings of the American Assoc. of Cancer Research Annual Meeting, 36:224, (1995).
Herblin, W., et al., Inhibition of Angiogenesis as a Strategy for Tumor Growth Control, Molecular and Chemical Neuropathology, 21:329-336, (1994).
Jennings, H.J., et al., Structural Determination and Serology of the Native Polysaccharide Antigen of Type-III Group B-Streptococcus, Can. J. of Biochem., 58(2):112-120, (1980).
Kim, K.J., et al., Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth in Vivo, Nature, 362:841-844, (1993).
Klagsbrun, M., et al., Regulators of Angiogenesis, Annu. Rev. Physiol., 53:217-239, (1991).
Kovacs, E.J., et al., Fibrogenic Cytokines and Connective Tissue Production, The FASEB Journal, 8:854-861, (1994).
Moses, M.A., et al., Identification of an Inhibitor of Neovascularization From Cartilage, Science, 248:1408-1410, (1990).
Murthy, S.M., et al., The Influence of Surgical Trauma on Experimental Metastasis, Cancer, 64(10):2035-2044, (1989).
Murthy, S.M., et al., Inhibition of Tumor Implantation at Sites of Trauma by Plasminogen Activators, Cancer, 68(8):1724-1730, (1991).
Ondrick, K., Ph.D., et al., Angiogenesis, Clinics in Podiatric Medicine and Surgery, 9(1):185-203, (1992).
Ono, M., et al., Induction of Human Microvascular Endothelial Tubular Morphogenesis by Human Keratinocytes: Involvement of Transforming Growth Factor-.alpha., Biochem. Biophys. Res. Commun., 189(2):601-609 (1992).
Parkinson, D.R., Present Status of Biological Response Modifiers in Cancer, The Amer. J. of Medicine, 99(6A Suppl.):54S-56S, (1995).
Pierce, G.F., et al., Pharmacologic Enhancement of Wound Healing, Annu. Rev. Med., 46:467-481, (1995).
Plate, K.H., et al., Molecular Mechanisms of Developmental and Tumor Angiogenesis, Brain Pathol., 4:207-218, (1994).
Polverini, P.J., The Pathophysiology of Agiogenesis, Crit. Rev. Oral Biol. Med., 6(3):230-247, (1995).
Quinn, T.E., et al., CM101, a Polysaccharide Antitumor Agent, Does Not Inhibit Wound Healing in Murine Models, J. Cancer Res. Clin. Oncol., 121:253-256, (1995).
Rubin, E., et al., Pathology, Lippincott, publ., pp. 75-95, (1994).
Sato, N., et al., Actions of TNF and IFN-.gamma. on Angiogenesis In Vitro, The J. of Investigative Dermatology, 95 (6 Suppl.):85S-89S, (1990).
Schackert, H.K., et al., Development of an Animal Model to Study the Biology of Recurrent Colorectal Cancer Origination From Mesenteric Lymph System Mestastases, Int. J. Cancer, 44:177-181, (1989).
Senger, D.R., et al., Vascular Permeability Factor, Tumor Angiogenesis and Stroma Generation, Invasion Metastasis, 14:385-394, (1994-1995).
Senger, D.R., et al., Vascular Permeability Factor (VPF, VEGF) in Tumor Biology, Cancer and Metastasis Reviews, 12:303-324, (1993).
Shah, M., et al., Control of Scarring in Adult Wounds by Neutralising Antibody to transforming Growth Factor .beta., The Lancet, 339:213-214, (1992).
Shweiki, D., et al., Induction of Vascular Endothelial Growth Factor Expression by Hypoxia and by Glucose Deficiency in Multicell Speroids: Implications for Tumor Angiogenesis, Proc. Natl. Acad. Sci. USA, 92:768-772, (1995).
Shweiki, D., et al., Vascular Endothelial Growth Factor Induced by Hypoxia May Mediate Hypoxia-Initiated Angiogenesis, Nature, 359:843-845, (1992).
Stein, I., et al., Stabilization of Vascular Endothelial Growth Factors mRNA by Hypoxia and Hypoglycemia and Coregulation With Other Ischemia-Induced Genes, Molecular and Cellular Biology, 15(10):5363-5368, (1995).
Stout, A.J., et al., Inhibition of Wound Healing in Mice by Local Interferon .alpha./.beta. Injection, Int. J. Exp. Pathol., 74:79-85, (1993).
Turco, S.J., Intravenous Admixtures, Remington's Pharmaceutical Sciences, 18th ed.,
Abramovitch Rinat
Hellerqvist Carl G.
Neeman Michal
Wamil Barbara D.
Cunningham Thomas M.
Lubet Martha
Vanderbilt University
Yeda Research & Development Co. Ltd.
LandOfFree
Facilitation of wound healing with CM101/GBS toxin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Facilitation of wound healing with CM101/GBS toxin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Facilitation of wound healing with CM101/GBS toxin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1516105